HALEON PLC
LSE:HLN
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
312.05
397
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one HLN stock under the Base Case scenario is 336.95 GBX. Compared to the current market price of 380.3 GBX, HALEON PLC is Overvalued by 11%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
HALEON PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for HLN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
HALEON PLC
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Haleon PLC emerged as a significant player in the global consumer health market when it was spun off from GlaxoSmithKline in July 2022. As a standalone entity, Haleon focuses on delivering everyday health products that enhance personal well-being, relying on a portfolio brimming with trusted brands like Sensodyne, Panadol, and Voltaren. With an impressive presence in over 100 countries, the company capitalizes on the growing consumer shift towards preventative healthcare and wellness, offering a range of over-the-counter medications, oral health products, and vitamins. This strategic approach positions Haleon not only as a trusted name but also as a vital contributor to the ongoing trend of...
Haleon PLC emerged as a significant player in the global consumer health market when it was spun off from GlaxoSmithKline in July 2022. As a standalone entity, Haleon focuses on delivering everyday health products that enhance personal well-being, relying on a portfolio brimming with trusted brands like Sensodyne, Panadol, and Voltaren. With an impressive presence in over 100 countries, the company capitalizes on the growing consumer shift towards preventative healthcare and wellness, offering a range of over-the-counter medications, oral health products, and vitamins. This strategic approach positions Haleon not only as a trusted name but also as a vital contributor to the ongoing trend of self-care, making it an intriguing option for long-term investors seeking growth in resilient sectors.
As Haleon charts its path forward, the company emphasizes sustainable growth and innovation, seeking to resonate with health-conscious consumers amid an increasingly competitive landscape. By investing in research and development, Haleon aims to expand its product offerings and enhance its market position. The company's focus on operational efficiency, coupled with strategic partnerships and an agile supply chain, reflects its commitment to driving profitability and shareholder value. With a strong foundation rooted in consumer trust and a forward-looking vision, Haleon PLC stands ready to navigate the evolving health landscape, presenting an appealing narrative for investors drawn to enterprises poised for sustainable success.
Haleon PLC, formed from the consumer healthcare division of GlaxoSmithKline (GSK), focuses on several core business segments related to consumer health products. As of my last update in October 2023, the main segments include:
-
Pain Relief: This segment includes well-known analgesic products aimed at providing relief from pain. Well-established brands such as Panadol (paracetamol) and Advil (ibuprofen) are part of this category.
-
Oral Health: Haleon has a strong portfolio in oral care, featuring leading brands like Sensodyne, Aquafresh, and Biotene. These products address different aspects of oral hygiene, including sensitivity and general dental care.
-
Respiratory Health: This includes products designed to alleviate respiratory issues, such as cough and cold remedies. Brands like Vicks fall under this segment.
-
Digestive Health: This segment consists of products that aid digestive health, including treatments for digestive issues and regularity. Brands like Tums and Centrum may be included here.
-
Vitamins, Minerals, and Supplements (VMS): Haleon offers various dietary supplements under brands like Centrum and Ninja Kidz. This segment focuses on overall wellness and preventive health.
-
Beauty & Personal Care: Although primarily focused on health, Haleon also offers products in the beauty sector that support skin health and personal care.
These segments are designed to cater to a wide range of consumer needs in healthcare, promoting overall wellness and providing relief for common ailments. Haleon's focus on consumer healthcare aligns with ongoing trends toward self-medication and preventive healthcare.
Haleon PLC, a consumer healthcare company that demerged from GlaxoSmithKline, possesses several unique competitive advantages that differentiate it from its rivals. Here are some key factors:
-
Strong Brand Portfolio: Haleon boasts a diverse and well-established portfolio of trusted consumer health brands such as Sensodyne, Panadol, Voltaren, and Nicorette. These brands have strong recognition and loyalty among consumers, providing a competitive edge in the marketplace.
-
Focus on Consumer Health: Unlike many of its competitors that might have a broader healthcare focus, Haleon is exclusively centered on consumer health products. This allows for strategic specialization, targeting innovations and marketing specifically in this niche.
-
Investment in R&D: Haleon has the ability to invest significantly in research and development, allowing them to innovate new products and improve existing ones. Their focus on science-backed health solutions helps maintain credibility with consumers.
-
Global Reach: With a strong international presence, Haleon can leverage economies of scale and tap into various regional markets, which diversifies risk and enhances revenue opportunities.
-
Digital Transformation: Haleon is likely to be at the forefront of digital health trends, investing in e-commerce and digital marketing strategies that can create direct connections with consumers and enhance brand loyalty.
-
Commitment to Sustainability: With an increasing focus on sustainability, Haleon’s initiatives in reducing its environmental impact and promoting social responsibility can enhance its reputation and appeal to eco-conscious consumers.
-
Strong Supply Chain and Distribution Network: A robust supply chain and an established distribution network enable Haleon to efficiently deliver products to market, ensuring availability and responsiveness to consumer needs.
-
Regulatory Expertise: With a background in pharmaceuticals, Haleon has significant expertise in navigating regulatory environments, which can be a competitive advantage in ensuring compliance and speed to market for new products.
-
Loyalty Programs and Customer Engagement: Haleon’s ability to implement loyalty programs and engage directly with consumers can foster brand loyalty and repeat purchases.
-
Adaptability: The recent spin-off from GSK allows Haleon to be more agile and responsive in a fast-changing consumer health environment, tailoring its strategy to current market conditions without being bogged down by legacy bureaucratic processes.
These competitive advantages position Haleon favorably against rivals in the consumer healthcare market, enabling it to sustain growth and profitability.
HALEON PLC, as a consumer health company, faces a variety of risks and challenges that could impact its performance in the near future. Here are some key factors to consider:
-
Market Competition: The consumer health sector is highly competitive, with numerous players vying for market share. HALEON must continually innovate and differentiate its products to maintain its competitive edge against established brands and new entrants.
-
Supply Chain Disruptions: Ongoing global supply chain issues, exacerbated by factors such as geopolitical tensions, port congestion, or natural disasters, could affect HALEON's ability to produce and deliver its products on time.
-
Regulatory Changes: As a company in the healthcare sector, HALEON faces stringent regulatory scrutiny. Changes in regulations or consumer safety standards could necessitate adjustments in manufacturing processes or alter product formulations, impacting costs and timelines.
-
Consumer Behavior Shifts: Post-pandemic, consumer preferences are evolving. HALEON needs to adapt to trends such as increased demand for health and wellness products, e-commerce growth, and changing buying patterns, especially among younger consumers.
-
Cost Inflation: Rising raw material costs and inflationary pressures could impact profit margins. HALEON must effectively manage its cost structure and pricing strategies to mitigate these effects.
-
Economic Downturns: Economic uncertainty or downturns can lead to reduced consumer spending, affecting sales of HALEON's non-essential health products. Economic factors may also influence the performance of the company's core brands.
-
Intellectual Property Risks: The protection of HALEON's intellectual property is crucial. Loss of patents or challenges to existing patents can affect the company's competitive position and ability to maintain pricing power.
-
Digital Transformation: As consumers increasingly shift towards online purchasing and digital engagement, HALEON must invest in digital marketing and e-commerce strategies to stay relevant. Failure to effectively adapt could result in lost market share.
-
Sustainability Concerns: There is a growing emphasis on sustainability and eco-friendly practices among consumers. HALEON needs to ensure that its products and packaging align with these expectations to maintain brand loyalty.
-
Health Trends and Scientific Advances: The rapid evolution of health-related trends and scientific research can create both opportunities and challenges. HALEON must stay abreast of these changes to adjust its product offerings and marketing strategies accordingly.
-
Global Health Issues: The impact of global health issues, such as pandemics or other public health crises, may affect operational capabilities, demand for specific products, and overall market conditions.
In summary, HALEON PLC must navigate a complex landscape of risks and challenges to sustain growth and remain competitive in the consumer health market. Strategic planning, agility, and proactive risk management will be essential in addressing these issues effectively.
Revenue & Expenses Breakdown
HALEON PLC
Balance Sheet Decomposition
HALEON PLC
Current Assets | 4.7B |
Cash & Short-Term Investments | 531m |
Receivables | 2.2B |
Other Current Assets | 2B |
Non-Current Assets | 28.7B |
Long-Term Investments | 81m |
PP&E | 1.9B |
Intangibles | 26.4B |
Other Non-Current Assets | 377m |
Current Liabilities | 5.6B |
Accounts Payable | 3.6B |
Short-Term Debt | 48m |
Other Current Liabilities | 2B |
Non-Current Liabilities | 11.2B |
Long-Term Debt | 7.4B |
Other Non-Current Liabilities | 3.8B |
Earnings Waterfall
HALEON PLC
Revenue
|
11.2B
GBP
|
Cost of Revenue
|
-4.3B
GBP
|
Gross Profit
|
7B
GBP
|
Operating Expenses
|
-4.8B
GBP
|
Operating Income
|
2.1B
GBP
|
Other Expenses
|
-919m
GBP
|
Net Income
|
1.2B
GBP
|
Free Cash Flow Analysis
HALEON PLC
GBP | |
Free Cash Flow | GBP |
The company reported robust first-half results with significant improvements in gross margin and organic sales growth. Confidence remains high in the full-year guidance of 4-6% organic revenue growth, translating to 5-9% in H2. Higher A&P spending is anticipated to support brand investments and the Eroxon launch. The medium-term objective is reducing net debt to 2.5x EBITDA by year-end, bolstered by strong cash flows and strategic divestments. Despite easing inflation, the cost impact will persist but be partly offset by operational efficiencies. Overall, the portfolio is performing well, with notable strength in Centrum and Oral Care brands.
What is Earnings Call?
HLN Profitability Score
Profitability Due Diligence
HALEON PLC's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
HALEON PLC's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
HLN Solvency Score
Solvency Due Diligence
HALEON PLC's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
HALEON PLC's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HLN Price Targets Summary
HALEON PLC
According to Wall Street analysts, the average 1-year price target for HLN is 406.16 GBX with a low forecast of 343.4 GBX and a high forecast of 478.8 GBX.
Dividends
Current shareholder yield for HLN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
HLN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
HALEON PLC is a GB-based company operating in Personal Products industry. The company is headquartered in Brentford, Middlesex and currently employs 22,800 full-time employees. The company went IPO on 2022-07-18. Haleon plc is a consumer healthcare company. The firm's product portfolio is divided among five categories: Oral Health; Pain Relief; vitamins, minerals and supplements (VMS); Respiratory Health; Digestive Health, and Other. Its portfolio of brands includes Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax and Centrum. In addition, the Company also has local strategic brands, which include TUMS, ENO, Flonase, ChapStick, Emergen-C, Fenbid, Grand-Pa, and Dr.BEST. The firm operates its business units in three regions: North America; Europe, Middle East, and Africa (EMEA) and Latin America (LatAm), and Asia-Pacific (APAC).
Contact
IPO
Employees
Officers
The intrinsic value of one HLN stock under the Base Case scenario is 336.95 GBX.
Compared to the current market price of 380.3 GBX, HALEON PLC is Overvalued by 11%.